Shteinberg M, Haq IJ, Polineni D, Davies JC (2021) Cystic fibrosis. Lancet 397:2195–2211. https://doi.org/10.1016/S0140-6736(20)32542-3

Article  CAS  PubMed  Google Scholar 

CFTR2 Variant List History | CFTR2. https://cftr2.org/mutations_history. Accessed 11 Aug 2023

Veit G, Avramescu RG, Chiang AN et al (2016) From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27:424–433. https://doi.org/10.1091/mbc.E14-04-0935

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng SH, Gregory RJ, Marshall J et al (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827–834. https://doi.org/10.1016/0092-8674(90)90148-8

Article  CAS  PubMed  Google Scholar 

Ward CL, Omura S, Kopito RR (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121–127. https://doi.org/10.1016/0092-8674(95)90240-6

Article  CAS  PubMed  Google Scholar 

Jensen TJ, Loo MA, Pind S et al (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83:129–135. https://doi.org/10.1016/0092-8674(95)90241-4

Article  CAS  PubMed  Google Scholar 

Van Goor F, Hadida S, Grootenhuis PDJ et al (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106:18825–18830. https://doi.org/10.1073/pnas.0904709106

Article  PubMed  PubMed Central  Google Scholar 

Accurso FJ, Rowe SM, Clancy JP et al (2010) Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation. N Engl J Med 363:1991–2003. https://doi.org/10.1056/NEJMoa0909825

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardin E, Pastor A, Semeraro M et al (2021) Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem 213:113195. https://doi.org/10.1016/j.ejmech.2021.113195

Article  CAS  PubMed  Google Scholar 

Bobadilla JL, Macek M, Fine JP, Farrell PM (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. Hum Mutat 19:575–606. https://doi.org/10.1002/humu.10041

Article  CAS  PubMed  Google Scholar 

Pedemonte N, Lukacs GL, Du K et al (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115:2564–2571. https://doi.org/10.1172/JCI24898

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Pesce E, Sheppard DN et al (2018) Therapeutic approaches to CFTR dysfunction: From discovery to drug development. J Cyst Fibros 17:S14–S21. https://doi.org/10.1016/j.jcf.2017.08.013

Article  CAS  PubMed  Google Scholar 

Farinha CM, Sousa M, Canato S et al (2015) Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect 3:e00152. https://doi.org/10.1002/prp2.152

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiedorczuk K, Chen J (2022) Mechanism of CFTR correction by type I folding correctors. Cell 185:158-168.e11. https://doi.org/10.1016/j.cell.2021.12.009

Article  CAS  PubMed  Google Scholar 

Fiedorczuk K, Chen J (2022) Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators. Science 378:284–290. https://doi.org/10.1126/science.ade2216

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wainwright CE, Elborn JS, Ramsey BW et al (2015) Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220–231. https://doi.org/10.1056/NEJMoa1409547

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roda J, Pinto-Silva C, Silva IAI et al (2022) New drugs in cystic fibrosis: what has changed in the last decade? Therap Adv Chronic Dis 13:20406223221098136. https://doi.org/10.1177/20406223221098136

Article  Google Scholar 

Sagel SD, Khan U, Heltshe SL et al (2021) Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial Annals ATS 18:75–83. https://doi.org/10.1513/AnnalsATS.202002-144OC

Article  Google Scholar 

Lopes-Pacheco M (2019) CFTR Modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 10:1662. https://doi.org/10.3389/fphar.2019.01662

Article  CAS  PubMed  Google Scholar 

Middleton PG, Mall MA, Dřevínek P et al (2019) Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med 381:1809–1819. https://doi.org/10.1056/NEJMoa1908639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG (2023) CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet 402:1171–1184. https://doi.org/10.1016/S0140-6736(23)01609-4

Article  CAS  PubMed  Google Scholar 

Dreano E, Burgel PR, Hatton A et al (2023) Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription. Eur Respir J 62:2300110. https://doi.org/10.1183/13993003.00110-2023

Article  CAS  PubMed  Google Scholar 

Veit G, Vaccarin C, Lukacs GL (2021) Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. J Cyst Fibros 20:895–898. https://doi.org/10.1016/j.jcf.2021.03.011

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tewkesbury DH, Robey RC, Barry PJ (2021) Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe (Sheff) 17:210112. https://doi.org/10.1183/20734735.0112-2021

Article  PubMed  Google Scholar 

Ben Saad A, Vauthier V, Tóth Á et al (2021) Effect of CFTR correctors on the traffic and the function of intracellularly retained ABCB4 variants. Liver Int 41:1344–1357. https://doi.org/10.1111/liv.14839

Article  CAS  PubMed  Google Scholar 

Scano M, Benetollo A, Nogara L et al (2022) CFTR corrector C17 is effective in muscular dystrophy, in vivo proof of concept in LGMDR3. Hum Mol Genet 31:499–509. https://doi.org/10.1093/hmg/ddab260

Article  CAS  PubMed  Google Scholar 

Pedemonte N, Tomati V, Sondo E, Galietta LJV (2010) Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298:C866-874. https://doi.org/10.1152/ajpcell.00404.2009

Article  CAS  PubMed  Google Scholar 

Brusa I, Sondo E, Falchi F et al (2022) Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives. J Med Chem 65:5212–5243. https://doi.org/10.1021/acs.jmedchem.1c01897

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taniguchi S, Fukuda R, Okiyoneda T (2023) The multiple ubiquitination mechanisms in CFTR peripheral quality control. Biochem Soc Trans